Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
OBJECTIVE
The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral dose of a proton pump inhibitor, esomeprazole 20 mg and omeprazole 20 mg.


METHODS
A total of 14 Helicobacter pylori-negative male subjects participated in this study. Intragastric pH was monitored continuously for 6 hours after a single oral dose of omeprazole 20 mg and a single oral dose of esomeprazole 20 mg. Each administration was separated by a 7-day washout period.


RESULTS
During the 6-hour study period, the average pH after administration of esomeprazole was higher than that after the administration of omeprazole. Also during the 6-hour study period, each of pH > 2, 3, 3.5, 4, and 5 was maintained for a longer duration after administration of esomeprazole 20 mg than after administration of omeprazole 20 mg (median: 75.4% vs. 53.8%, p = 0.0138; 52.1% vs. 33.4%, p = 0.0188; 45.8% vs. 28.2%, p = 0.0262; 42.5% vs. 20.7%, p = 0.0414; 35.8% vs. 11.6%, p = 0.0262; respectively).


CONCLUSIONS
In Helicobacter pylori-negative healthy male subjects, single oral administration of esomeprazole 20 mg increased the intragastric pH more rapidly than single oral administration of omeprazole 20 mg.
Hiroshi
H
Iida
Masahiko
M
Inamori
Kotone
K
Okuno
Yusuke
Y
Sekino
Eiji
E
Sakai
Hidenori
H
Okubo
Takuma
T
Higurashi
Hiroki
H
Endo
Kunihiro
K
Hosono
Masato
M
Yoneda
Tomoko
T
Koide
Hirokazu
H
Takahashi
Ayumu
A
Goto
Kensuke
K
Kubota
Satoru
S
Saito
Shin
S
Maeda
Atsushi
A
Nakajima
Eiji
E
Gotoh
D000284:Administration, Oral; D000328:Adult; D018592:Cross-Over Studies; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics / Q000378:metabolism; D064098:Esomeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D005838:Genotype; D064368:Healthy Volunteers; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007564:Japan; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D010641:Phenotype; D054328:Proton Pump Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016896:Treatment Outcome; D055815:Young Adult
D054328:Proton Pump Inhibitors; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole; D064098:Esomeprazole